Articles By Anuja Singh
Can Parallel Bio’s $21M Bet on Immune Organoids Cut Drug Failure Rates from 95%…
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
By
Can BullFrog AI and Sygnature Discovery’s $30M Alliance Reshape How Global Biopharma Uses AI…
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack Drug Discovery?
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using AI to Unlock Sex-Specific Drug Combos…
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the Map of Chiral Drug Discovery?
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next Breakthrough in Atopic Dermatitis Treatment?
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
Can Parallel Bio’s $21M Bet on Immune Organoids Cut Drug Failure Rates from 95%…
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
Can BullFrog AI and Sygnature Discovery’s $30M Alliance Reshape How Global Biopharma Uses AI…
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack Drug Discovery?
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using AI to Unlock Sex-Specific Drug Combos…
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the Map of Chiral Drug Discovery?
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next Breakthrough in Atopic Dermatitis Treatment?
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…